LYVE1 and neoplasm: Fc-EndoP125A treatment did not decrease the total amount of tumor vasculature, but mice exhibited smaller tumor vessels and markedly decreased CD34+ and LyVE-1+ tumor vessel density compared to PBS- and Rituximab-treated mice (Figure 5E,H).